We are pleased to present below all posts archived in 'April, 2014'. If you still can't find what you are looking for, try using the search box.
Cardiff, UK – 22 April 2014 – EKF Diagnostics (www.ekfdiagnostics.com), the global in vitro diagnostics business, announces that it has acquired Selah Genomics, Inc. and DiaSpect Medical AB. Sweden based DiaSpect manufactures desktop hemoglobin analyzers, whilst Selah, of South Carolina is a service provider that supplies molecular diagnostics tests for the development of personalized medicine.
Read the rest of entry »
OXFORD, UK and MARLBOROUGH, MA, APR. 21, 2014 (GLOBE NEWSWIRE) – Oxford Immunotec Global PLC (NASDAQ: OXFD) today announced that it has received a Queen’s Award for Enterprise – the UK’s highest accolade in business success.
Roche is pleased to announce the launch of the Elecsys® Syphilis test. The new Elecsys assay enables the detection of total antibodies to T. pallidum (detection of IgG & IgM antibodies against TpN15, TpN17 & TpN47) and complements the Mediace® Rapid Plasma Reagin (RPR) and T. pallidum Latex Agglutination® (TPLA) Roche assays, allowing reliable detection of infection and treatment monitoring for syphilis
11th April 2014, Cobham, UK - The possibility of patients with pancreatic cancer being able to have their cancer tissue ‘profiled’ to understand how they will react to different treatments before they are given to them has moved a lot closer, a new research paper shows, published in the peer reviewed journal PLOS ONE. This will enable more accurate profiling and the best drug selection for each individual. Trials are being planned to undertake the final stage of the process.
EKF Diagnostics (www.ekfdiagnostics.com), the global in vitro diagnostics business, announces that it has acquired Separation Technology, Inc. (STI), the Florida based manufacturer of in vitro diagnostics devices for hematology testing.
Now available in the UK from Alpha Laboratories (Eastleigh, Hants), STAT-NAT® is a new protective compound that stabilises the activity of enzymes for a very long time with no temperature controlled storage requirements. This proprietary technology developed by Sentinel (Milan, Italy), provides an optimal and convenient basic platform useful for kits, “home brew” routine tests, and for the development of new assays.
Who are the BIVDA Members
Member Press Releases
Point of Care Directory
News, Policy and Media
BIVDA Press Releases